Advertisement


Bruce D. Cheson, MD, and Richard I. Fisher, MD, on Lymphoma: Treatment Considerations

Pan Pacific Lymphoma Conference 2018

Advertisement

Bruce D. Cheson, MD, of Georgetown University Hospital, and Richard I. Fisher, MD, of Fox Chase Cancer Center, discuss ways to incorporate PET and CT scanning into standard of care for and research studies on lymphoma.



Related Videos

Lymphoma

Steven M. Horwitz, MD, on CD 30+ PTCL Subtypes: Treatment Update

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses aggressive subtypes of peripheral T-cell lymphoma and the coming data that may help clarify what could be the most effective treatments.

CNS Cancers
Lymphoma

Philip J. Bierman, MD, on DLBCL: Managing Patients at Risk of CNS Involvement and Systemic Disease

Philip J. Bierman, MD, of the University of Nebraska Medical Center, discusses how to identify and treat the 1% to 2% of patients with diffuse large B-cell lymphoma who have central nervous system involvement as well as systemic sites at the time of diagnosis.

Lymphoma

Jonathan W. Friedberg, MD, on Follicular Lymphoma: Novel Combination Therapies

Jonathan W. Friedberg, MD, of the University of Rochester Medical Center, discusses treatments that enhance progression-free and overall survival and clear minimal residual disease—obinutuzumab plus chemotherapy, lenalidomide, and rituximab—and the types of lymphoma patients who may benefit.

Lymphoma
Immunotherapy

Stephen M. Ansell, MD, PhD, on Hodgkin Lymphoma: Beyond Checkpoint Inhibitors

Stephen M. Ansell, MD, PhD, of the Mayo Clinic, discusses the efficacy of PD-1 blockade in Hodgkin lymphoma, new findings related to PD-1 therapy, current combination approaches, and future treatments.

Symptom Management
Immunotherapy

Susan Blumel, RN, BSN, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, on Managing Toxicities of Immunotherapy

Susan Blumel, RN, BSN, of the University of Nebraska Medical Center, and Laura J. Zitella, MS, RN, ACNP-BC, AOCN, of Stanford Health Center, discuss immunotherapy, CAR T-cell toxicities, and the principles of team management.

Advertisement

Advertisement




Advertisement